A leukemia drug’s first results with two other medicines will be presented in December.
Kura Oncology (KURA) and Kyowa Kirin (4151) will present data on ziftomenib, their leukemia drug, at the 2026 ASH Annual Meeting. Key presentations include combination results with quizartinib and gilteritinib, longer-term data with venetoclax and azacitidine, and exploratory analysis in additional AML subtypes. The companies aim to establish ziftomenib as a preferred menin inhibitor for combination treatments. An investor webcast is scheduled for December 15, 2026.
How this was made
The 30-second read
Why it matters
The announcements provide the first public efficacy and safety signals for these combinations, a key catalyst for KURA's pipeline valuation.
Market read
First‑time disclosure of early clinical data on a promising AML therapy; likely to move KURA stock and influence the AML biotech niche.
What to watch
Potential safety signals or modest efficacy could temper enthusiasm despite headline‑friendly data.
Background
Kura Oncology (Nasdaq: KURA) and Japan's Kyowa Kirin disclosed eight ASH abstracts on their menin inhibitor ziftomenib, covering new FLT3‑inhibitor combos and longer‑term frontline data.
Ticker impact
Kura Oncology announced eight abstracts on ziftomenib, including first combination data with quizartinib and gilteritinib, to be presented at the ASH 2026 meeting.
likely upward pressure as market prices in the promising trial results
First public disclosure of combination trial results; biotech stocks typically react strongly to early efficacy and safety data.
Market effects
Positive data may lift other menin‑inhibitor and AML‑focused biotech peers.
US biotech sector could see modest gains; Japanese partner Kyowa Kirin may benefit indirectly.
Adds optimism to the global AML therapeutic pipeline.
Counterpoint
Early‑phase data may be limited; investors could wait for Phase 3 results before committing.
Key entities
- companyKura Oncology
US‑listed biotech developing ziftomenib for AML.
- companyKyowa Kirin
Japanese partner collaborating on ziftomenib development.
